We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Serum Biomarkers Predict Women at Risk of Preeclampsia

By LabMedica International staff writers
Posted on 09 Aug 2015
The screening of pregnant women to identify those at risk of preeclampsia may improve the prognosis for the mother and the infant and accordingly, there has been an intense search for the early biomarkers of preeclampsia. More...


Severe preeclampsia can affect the mother by damaging the kidneys, liver and other organs and, in really severe cases, cause seizures and coma. There is often less fluid than normal around the baby and the placenta can be affected, restricting blood flow and nutrients necessary for the baby's growth.

Scientists at the Mexican Institute of Social Security (Mexico City, Mexico) carried out a longitudinal study on 252 pregnant women attending two obstetric referral hospitals. Women visited the hospital once a month until delivery. Fasting blood samples from a peripheral vein were obtained after a 10 hour fast and collected in anti-coagulation vacuum-sealed tubes. Clinical records were assessed after every visit to identify women diagnosed with preeclampsia by the obstetrician responsible for her care, which included systolic blood pressure and diastolic blood pressure measurements.

Biochemical determinations were conducted and asymmetric dimethylarginine (ADMA), homocysteine,(Hcy), and vitamin B6 (VB6) and measured by high-performance liquid chromatography (Waters 600, Milford, MA, USA) , with a fluorescence detector (Model 474) and 4.6 × 250-mm columns (ODS Hypersil, Keystone Scientific; Bellefonte, PA, USA). VB12 was measured by chemiluminescence using commercial kits on the Immulite1000 Systems (Siemens; Erlangen, Germany), and folic acid (FA) was measured in whole blood by the microbiological method.

The team found that of the 252 women in their study, based at two hospitals, 49 in the group who went on to develop preeclampsia had raised levels of ADMA and Hcy a month before onset of the condition. The levels of these two biomarkers were raised regardless of the eventual severity of the preeclampsia. There were no significant differences in the concentrations of Hcy and ADMA between the mild preeclampsia and the severe preeclampsia groups; however, the group with mild preeclampsia exhibited intermediate values between the groups with no complications and with severe preeclampsia. Analysis of deltas demonstrated that ADMA and Hcy increased by 124 ± 27 nmol and 1,177 ± 278 nmol respectively, at one month prior to preeclampsia and such increases did not differ between mild and severe preeclampsia groups.

Mardia Lopez-Alarcon, PhD, the lead author of the study said, “While for most of the women we tested the levels of ADMA and Hcy remained constant throughout pregnancy, these serum biomarkers were clearly raised a month before onset in women who went on to develop pre-eclampsia. Of the other factors we tested, obesity and low levels of folic acid at the start of the pregnancy, as all the mothers received folic acid supplementation, were also independently linked to preeclampsia.” The study was published on July 22, 2015, in the journal BJOG: An International Journal of Obstetrics and Gynaecology.

Related Links:

Mexican Institute of Social Security 
Waters
Siemens



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The new study aims to enhance colorectal cancer prevention by identifying polyp molecular signals (Photo courtesy of Shutterstock)

RNA Screening Test Could Detect Colon Polyps Before They Become Cancerous

Colorectal cancer has become a growing health crisis, especially as it increasingly affects younger adults in their 20s, 30s, and 40s, while screening rates remain low. Colorectal cancer is now the leading... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.